Drugs Made In America Acquisition II Corp Unit
DMIIU
75 hedge funds and large institutions have $456M invested in Drugs Made In America Acquisition II Corp Unit in 2025 Q3 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$26.9M |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$26.9M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$23.4M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$19.9M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$19.9M |
Top Sellers
DMIIU Hedge Fund Activity: Q3 2025 in Review
75 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Unit (DMIIU) for Q3 2025, worth a combined $456M.
Buyers outnumbered sellers: 75 funds opened new DMIIU positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $26.9M.
- 75 institutional investors held Drugs Made In America Acquisition II Corp Unit (DMIIU) as of Q3 2025, up from 0 in Q2 2025.
- Funds reported $456M of Drugs Made In America Acquisition II Corp Unit stock for Q3 2025.
- 75 funds opened new Drugs Made In America Acquisition II Corp Unit positions in Q3 2025 and 0 closed out, a net change of +75 holders.
- The largest Drugs Made In America Acquisition II Corp Unit buyer in Q3 2025 was Magnetar Financial, an estimated $26.9M added.
Based on aggregated 13F filings for Q3 2025.